X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Luforbec (formoterol) oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease.
Lead Product(s): Formoterol Fumarate,Beclomethasone Dipropionate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Luforbec
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.
Lead Product(s): Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area: Dermatology Product Name: AKP01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $83.1 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 01, 2021
Details:
European Commission has granted the marketing authorization for Trimbow inhalation powder delivered through NEXThaler (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) for treatment of moderate to severe COPD.
Lead Product(s): Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trimbow
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients. This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe COPD patients.
Lead Product(s): Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trimbow
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
Chiesi Farmaceutici and Bayer have entered into a co-promotion agreement for Clenil® and Foster® in China, two products of Chiesi Group’s established portfolio in the respiratory therapeutic area.
Lead Product(s): Beclomethasone Dipropionate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Clenil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
